BRAF and neoplasm: Sorafenib, an orally available multikinase inhibitor of VEGFR-2/-3, PDGFR-β, B-Raf, C-Raf, FLT-3, and RET, has shown an anti-tumour activity in preclinical models of breast, colon, and pancreatic cancer, as well as in a phase I clinical trial in solid tumours (Wilhelm et al, 2004; Beeram et al, 2005; Strumberg et al, 2005) and in a phase II trial in metastatic thyroid cancer (Kloos et al, 2009).